rs119464998
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_001079802.2(FKTN):āc.1112A>Gā(p.Tyr371Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000199 in 1,610,638 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.000020 ( 0 hom., cov: 32)
Exomes š: 0.000020 ( 0 hom. )
Consequence
FKTN
NM_001079802.2 missense
NM_001079802.2 missense
Scores
12
6
1
Clinical Significance
Conservation
PhyloP100: 6.54
Genes affected
FKTN (HGNC:3622): (fukutin) The protein encoded by this gene is a putative transmembrane protein that is localized to the cis-Golgi compartment, where it may be involved in the glycosylation of alpha-dystroglycan in skeletal muscle. The encoded protein is thought to be a glycosyltransferase and could play a role in brain development. Defects in this gene are a cause of Fukuyama-type congenital muscular dystrophy (FCMD), Walker-Warburg syndrome (WWS), limb-girdle muscular dystrophy type 2M (LGMD2M), and dilated cardiomyopathy type 1X (CMD1X). Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Nov 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.955
PP5
Variant 9-105620001-A-G is Pathogenic according to our data. Variant chr9-105620001-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 3215.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=2, Pathogenic=2, Likely_pathogenic=3}. Variant chr9-105620001-A-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FKTN | NM_001079802.2 | c.1112A>G | p.Tyr371Cys | missense_variant | 10/11 | ENST00000357998.10 | NP_001073270.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FKTN | ENST00000357998.10 | c.1112A>G | p.Tyr371Cys | missense_variant | 10/11 | 5 | NM_001079802.2 | ENSP00000350687.6 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152086Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152086
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000279 AC: 7AN: 251166Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135770
GnomAD3 exomes
AF:
AC:
7
AN:
251166
Hom.:
AF XY:
AC XY:
3
AN XY:
135770
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000199 AC: 29AN: 1458552Hom.: 0 Cov.: 29 AF XY: 0.0000179 AC XY: 13AN XY: 725832
GnomAD4 exome
AF:
AC:
29
AN:
1458552
Hom.:
Cov.:
29
AF XY:
AC XY:
13
AN XY:
725832
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152086Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74290
GnomAD4 genome
AF:
AC:
3
AN:
152086
Hom.:
Cov.:
32
AF XY:
AC XY:
2
AN XY:
74290
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
3
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:7Uncertain:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Pathogenic:3Uncertain:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2009 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Nov 14, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 04, 2023 | Variant summary: FKTN c.1112A>G (p.Tyr371Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251166 control chromosomes. c.1112A>G has been reported in the literature as a compound heterozygous genotype in two patients (two sisters) presenting with congenital muscular dystrophy, mental retardation, and posterior fossa malformation including cysts, and brain atrophy at Brain MRI (Vuillaumier-Barrot_2009), as a compound heterozygous genotype in a patient with Fukuyama-type congenital muscular dystrophy (FCMD) (Kobayashi_2001, Tachikawa_2012) and as a complex genotype with reportedly pathogenic variants in three different genes to include this one, RBM20 and HCN4 in an individual with noncompaction cardiomyopathy (NCCM) (van Waning_2018). At least one publication reports experimental evidence evaluating an impact on protein function reporting that the mutant accumulated in the ER instead of Golgi (WT) (Tachikawa_2012). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (Lp/P, n=2; VUS, n=2). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Walker-Warburg congenital muscular dystrophy Pathogenic:2
Likely pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Oct 30, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 371 of the FKTN protein (p.Tyr371Cys). This variant is present in population databases (rs119464998, gnomAD 0.01%). This missense change has been observed in individuals with congenital muscular dystrophy (PMID: 11165248, 19179078; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 3215). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FKTN protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects FKTN function (PMID: 17034757, 22275357). For these reasons, this variant has been classified as Pathogenic. - |
Dilated cardiomyopathy 1X Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 26, 2024 | - - |
Autosomal recessive limb-girdle muscular dystrophy type 2M Pathogenic:1
Pathogenic, criteria provided, single submitter | curation | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Feb 01, 2024 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 21, 2024 | The p.Y371C variant (also known as c.1112A>G), located in coding exon 8 of the FKTN gene, results from an A to G substitution at nucleotide position 1112. This alteration has been reported in subjects with features of Fukuyama-type congenital muscular dystrophy (FCMD) and in a noncompaction cardiomyopathy cohort (Kobayashi K et al. FEBS Lett, 2001 Feb;489:192-6; Vuillaumier-Barrot S et al. Neuromuscul Disord, 2009 Mar;19:182-8; van Waning JI et al. J Am Coll Cardiol, 2018 02;71:711-722). Studies suggest this alteration may have an impact on protein function, however the exact function of fukutin is yet unknown (Xiong H et al. Biochem Biophys Res Commun, 2006 Dec;350:935-41; Tachikawa M et al. J Biol Chem, 2012 Mar;287:8398-406). The tyrosine at codon 371 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;.;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;M;M;M
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;D;.;D
REVEL
Pathogenic
Sift
Uncertain
.;D;.;D
Sift4G
Pathogenic
D;D;D;D
Polyphen
D;D;.;.
Vest4
MVP
MPC
0.15
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at